SightGlass DOT Lenses Show 67% Slower Myopia Progression in Children: Key Findings from the CATHAY Study
Myopia, or nearsightedness, is a growing global health concern, particularly among children. A recent study presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting in 2023 highlights a promising advancement in myopia management: SightGlass Vision’s Diffusion Optics Technology (DOT) spectacle lenses. The CATHAY study, conducted in China, demonstrated significant slowing of myopia progression in children aged 6 to 13 years.
Key Findings from the CATHAY Study
The CATHAY study, which enrolled 172 children, found that those wearing DOT lenses experienced a 67% reduction in myopia progression over two years compared to a control group. Key results include:
- 0.78 D lower myopia progression (an average of 0.78 diopters less than controls)
- 0.4 mm lower increase in axial length (a measure of eye elongation, linked to myopia severity)
- 59% of lens wearers had myopia progression of 0.5 D or less, compared to 19% in the control group.
Notably, children aged 6 to 10 showed even greater benefits, with over 1 diopter of myopia control compared to controls. These findings suggest DOT lenses may be particularly effective for younger patients.
How DOT Lenses Work
DOT lenses use a specialized optical design to create a “defocus” effect, which may help slow the elongation of the eyeball. This approach is similar to other myopia control strategies, such as multifocal contact lenses and atropine eye drops, but offers a non-invasive, spectacle-based alternative.
Comparison to Previous Studies
The CATHAY study builds on earlier research, including the North American CYPRESS trial. However, the CATHAY study was conducted under normal daily conditions, unlike the CYPRESS study, which was influenced by pandemic-related lifestyle changes. “This is the first time we’ve seen 24-month results in normal conditions,” noted David Webley, senior director of clinical affairs at SightGlass Vision.
Limitations and Next Steps
While the results are promising, the study is still undergoing peer review, and the lenses are not yet FDA approved. Long-term safety and efficacy data are needed. A third year of CATHAY study data is currently being collected for presentation in 2024.
Expert Insights
Dr. Webley emphasized the potential of DOT lenses for early intervention. “Practitioners can be confident in recommending these lenses for younger children, who may benefit most from early myopia control,” he said.
FAQ: Myopia Control with DOT Lenses
What is myopia progression?
Myopia progression refers to the worsening of nearsightedness over time, often measured in diopters (D). It is linked to an increased risk of complications like retinal detachment and glaucoma.
Are DOT lenses safe for children?
Studies to date have not reported increased astigmatism or other adverse effects. However, consultation with an eye care professional is essential before starting any myopia control treatment.
How do DOT lenses compare to other treatments?
DOT lenses offer a non-invasive alternative to atropine drops or contact lenses. Their effectiveness in slowing axial length growth is comparable to other established methods, though long-term data is still emerging.
Conclusion
The CATHAY study adds to the growing body of evidence supporting the use of DOT lenses as a viable option for myopia management in children. As research continues, these lenses may become a critical tool in preventing severe myopia and its associated complications. Parents and healthcare providers are encouraged to stay informed about ongoing studies and consult with ophthalmologists to determine the best approach for individual cases.